Loading…
Radiosynthesis of 3H‐ and 14C‐labeled Veliparib
Veliparib, a potent PARP inhibitor used against multiple cancerous cells such as metastatic melanoma, breast, non‐small cell lung cancer (NSCLC) and prostatic cancer, is required for absorption, distribution, metabolism and excretion (ADME) and environmental toxicology assessments studies. Tritium‐l...
Saved in:
Published in: | Journal of labelled compounds & radiopharmaceuticals 2021-07, Vol.64 (9), p.356-362 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Veliparib, a potent PARP inhibitor used against multiple cancerous cells such as metastatic melanoma, breast, non‐small cell lung cancer (NSCLC) and prostatic cancer, is required for absorption, distribution, metabolism and excretion (ADME) and environmental toxicology assessments studies. Tritium‐labeled Veliparib was prepared via the tritiodebromination using tritium gas (T2) in two steps. [14C]Veliparib was achieved through an asymmetric synthetic route in seven radioactive steps starting from [14C] (S)‐benzyl 2‐aminopropanoate.
Veliparib, a potent PARP inhibitor used against multiple cancerous cells such as metastatic melanoma, breast, non‐small cell lung cancer (NSCLC) and prostatic cancer, is required for ADME and environmental toxicology assessments studies. Tritium‐labeled Veliparib was prepared via the tritiodebromination using tritium gas (T2) in two steps. [14C]Veliparib was achieved through an asymmetric synthetic route in seven radioactive steps starting from [14C] (S)‐benzyl 2‐aminopropanoate. |
---|---|
ISSN: | 0362-4803 1099-1344 |
DOI: | 10.1002/jlcr.3928 |